VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients
sponsored by Boston Scientific
Author: SPONSOREDPublished: 4 October 2017
Prep: Cook: Serves:
Watch deep brain stimulation (DBS) experts Professor Pollo, Professor Timmermann, Professor Visser-Vanderwalle and Professor Volkmann explain the benefits of novel directional DBS systems for improved symptom control and fewer side effects
Every human brain is unique and every course of Parkinson’s disease has its own characteristics. In deep brain stimulation (DBS) therapy, physicians aim to target a very specific part of the brain – the subthalamic nucleus – in order to mitigate Parkinson’s symptoms.
Up until now, conventional DBS systems only allowed for stimulation with ring electrodes. With these electrodes, stimulation took the form of a ring around the electrode in the lead that was implanted into the patient’s brain. This meant that while physicians tried to target a very specific area of the brain, they always ran the risk of stimulating its neighbouring regions – since they could not steer the stimulation precisely. Unintended and unwanted stimulation could cause side effects such as speech problems.
The latest generation of DBS devices allow physicians to precisely steer the stimulation to target one specific area of the brain – significantly reducing side effects from unwanted stimulation. Our directional DBS systems use novel lead designs with segmented electrodes that allow the activation of individual electrode contacts. In addition, the technology in the pulse generator that powers the leads – the Multiple Independent Current Control (MICC) technology – allows the physician to specify exactly the amount of current needed for every contact of the electrode.
Through activating specific electrode contacts, and defining the amount of stimulation for each contact, stimulation precision is significantly increased. It is similar to shining a light on a specific spot with a flashlight. With the new systems, physicians now have full control of the stimulation steering and an increased set of stimulation options.
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Man with Parkinson’s sets sights on 3,600-mile world record
Robin Buttery will row the length of the Indian Ocean
7 days ago
New wearable medical device for Parkinson’s disease to launch this year
The Imperial College London Innovation Fund, UK, has invested £205,000 to support UK-based tech company Charco Neurotech in its development of a non-invasive medical device for people with Parkinson’s disease. CUE1, a circular device that attaches to the sternum with medical adhesives, uses specialised vibration to help alleviate physical symptoms of Parkinson’s disease. Initial user testing among people with the condition found that the device improved movement by an average of 16%, with testers reporting benefits for walking and fine motor tasks. Lucy Jung, CEO and co-founder of Charco Neurotech, said: “We believe that CUE1 has the potential to significantly improve [Parkinson’s disease] symptoms through its unique controlled vibration technology. We are excited to continue our work on the device and we look forward to the outcome of our proposed clinical trials.” Charco Neurotech will use the Imperial College investment to initiate a clinical trial and fund the device’s manufacture for…
New study brings scientists a “vital step” closer to understanding Parkinson’s disease
A new study from scientists at the University of Cambridge, UK, has brought researchers “a vital step” closer to discovering the origins of Parkinson’s disease. The research, published in the scientific journal ‘Nature Communications’, offered insights on the protein alpha-synuclein, which clumps together in the neurons of people with Parkinson’s. The study focused on how the protein functions in those without the condition and revealed that it sticks to the inner side of the plasma membrane of nerve cells, but not the outer membrane – an insight that could help in the search for a cure. Lead study author, Dr Giuliana Fusco, said: “This study could unlock more information about this debilitating neurodegenerative disorder that can leave people unable to walk and talk. If we want to cure Parkinson’s, first we need to understand the function of alpha-synuclein, a protein present in everyone’s brains.”
Could a prostate drug lower the risk of Parkinson’s disease?
Researchers in the US, Denmark and China have found that a type of medication used to treat enlarged prostate, known as alpha-blockers, is associated with a lower risk of Parkinson’s disease. As part of the study, the research team analysed patient data from 150,000 men using medications like the alpha-blocker terazosin – which has previously been shown to slow Parkinson’s disease progression in animals – and compared their findings to data from 150,000 men using the alpha-blocker tamsulosin. They found that men taking terazosin were 12 to 37% less likely to develop Parkinson’s disease. Jacob Simmering, corresponding author of the study, said: “Despite the relative differences in population and health care system structure, we found a similar protective effect in both [the US and Denmark]. “If these results are confirmed through further investigation, especially a randomised clinical trial, terazosin may provide neuroprotection and potentially prevent – and not just manage…